Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It has also designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.
์ข
๋ชฉ ์ฝ๋ NXL
ํ์ฌ ์ด๋ฆNexalin Technology Inc
์์ฅ์ผSep 16, 2022
CEOWhite (Mark)
์ง์ ์6
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃSep 16
์ฃผ์1776 Yorktown
๋์HOUSTON
์ฆ๊ถ ๊ฑฐ๋์NASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐUnited States of America
์ฐํธ ๋ฒํธ77056
์ ํ18322600222
์น์ฌ์ดํธhttps://nexalin.com
์ข
๋ชฉ ์ฝ๋ NXL
์์ฅ์ผSep 16, 2022
CEOWhite (Mark)
์ง๋ 5๋
๋์ ์ด
0.00
USD์ ๋ฐฐ๋น๊ธ์ด ๋ถ๋ฐฐ๋์์ต๋๋ค.

๋ฐ์ดํฐ ์์